TJP3 is reported to participate in drug tolerance in long non-coding RNA NEAT1-mediaed tumor invasion in ovarian cancer [28], and it is involved in treatment sensitivity of FPDHP in human cancer cells [29]. Here, TJP3 is linked to ovarian carcinoma.